Real-World Utilization of Drug X in the Outpatient Setting

Infections caused by multi-drug resistant organisms are on the rise globally and the need for novel antibiotic therapies or new uses for existing antibiotic therapies is higher than ever. This on-going retrospective observational chart review study seeks to evaluate how Drug X is being prescribed in the outpatient setting. Currently, Drug X is approved by the United States Food and Drug Administration for the treatment of complicated intra-abdominal infections. However, thus far, the study has shown that Drug X is being used as definitive treatment in a multitude of other infections including bone and joint infections, cardiac infections, diabetic foot infections, gastrointestinal infections, genitourinary infections, respiratory infections, sepsis, skin and soft tissue infections, and infections classified as “other.” Organisms that may be susceptible to Drug X include multi-drug resistant (MDR) Acinetobacter, Klebsiella, some Staphylococcus aureus organisms, and Pseudomonas aeruginosa. In addition, adverse events, such as development of Clostridium difficile, death, or hospital admission attributable to the medication, have not been observed.